Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the current standard of care and new chemotherapy options for patients with advanced …

As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease
and the majority of patients with locally advanced disease will eventually develop metastatic …

A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral
dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine …

Purpose The conversion rate of tegafur (a component of S-1) to fluorouracil (FU) differs in
Asians and whites because of polymorphic differences in the CYP2A6 gene. S-1 with …

The aim of this study was to investigate the efficacy and safety of an oral fluoropyrimidine
derivative, S-1, in patients with advanced biliary tract cancer. Patients with pathologically …

Metastatic gastric cancer remains a non-curative disease. Palliative chemotherapy has been
demonstrated to prolong survival without quality of life compromise. Many single-agents and …

Background Hand–foot syndrome (HFS) is a common side-effect of capecitabine. S-1 is an
oral fluoropyrimidine with comparable efficacy to capecitabine in gastrointestinal cancers but …

Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the role and evolution of chemotherapy for advanced gastric cancer. Discuss results of …

We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug
tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium …

The fluoropyrimidine anticancer agent 5-fluorouracil (5-FU) is active in a wide range of solid
tumors, particularly gastric, colorectal, and head and neck cancers. Whilst infusional 5-FU is …